Miromatrix Medical Closes $27M Series C Preferred Stock Financing Round

Miromatrix Medical, a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives, closed a $27 million series C preferred stock financing round. Faegre Drinker represented Miromatrix Medical in the matter, with corporate professionals from the Minneapolis and Indianapolis offices providing counsel. The shares of series C preferred stock converted into common stock in connection with the company's recent initial public offering (IPO).